ADPT

SEC source: 0001062993-25-004800 · form4.xml · nonDerivative · entry 1

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 67,349

SEC source: 0001062993-25-003241 · form4.xml · derivative · entry 6

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 99,107 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option would have expired on June 9, 2025.

F4 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001062993-25-003241 · form4.xml · nonDerivative · entry 4

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,576,701

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option would have expired on June 9, 2025.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to 8.69, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001062993-25-003241 · form4.xml · nonDerivative · entry 3

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,675,808

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option would have expired on June 9, 2025.

SEC source: 0001062993-25-003241 · form4.xml · derivative · entry 5

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 99,107

Underlying: Common Stock · 186,080 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option would have expired on June 9, 2025.

F4 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001062993-25-003241 · form4.xml · nonDerivative · entry 2

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,576,701

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option would have expired on June 9, 2025.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to 8.67, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001062993-25-003241 · form4.xml · nonDerivative · entry 1

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,762,781

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option would have expired on June 9, 2025.

SEC source: 0001062993-25-002744 · form4.xml · derivative · entry 9

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 285,187

Underlying: Common Stock · 211,160 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option expires on June 9, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001062993-25-002744 · form4.xml · nonDerivative · entry 6

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,576,701

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option expires on June 9, 2025.

F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to 8.91, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001062993-25-002744 · form4.xml · nonDerivative · entry 5

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,787,861

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option expires on June 9, 2025.

SEC source: 0001062993-25-002744 · form4.xml · derivative · entry 8

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 496,347

Underlying: Common Stock · 158,921 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option expires on June 9, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001062993-25-002744 · form4.xml · nonDerivative · entry 4

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,576,701

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option expires on June 9, 2025.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to 8.69, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001062993-25-002744 · form4.xml · nonDerivative · entry 3

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,735,622

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option expires on June 9, 2025.

SEC source: 0001062993-25-002744 · form4.xml · derivative · entry 7

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 655,268

Underlying: Common Stock · 100,287 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option expires on June 9, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001062993-25-002744 · form4.xml · nonDerivative · entry 2

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,576,701

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option expires on June 9, 2025.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to 8.56, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001062993-25-002744 · form4.xml · nonDerivative · entry 1

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,676,988

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option expires on June 9, 2025.

SEC source: 0001062993-24-019373 · form4.xml · nonDerivative · entry 1

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,330

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade.

SEC source: 0001062993-24-017564 · form4.xml · derivative · entry 2

BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2024-10-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The options are fully exercisable.

SEC source: 0001062993-24-017564 · form4.xml · nonDerivative · entry 1

BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 253,290

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-24-015606 · form4.xml · nonDerivative · entry 1

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 139,365

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 23, 2024.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $4.415 to $4.62, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001062993-24-010709 · form4.xml · nonDerivative · entry 1

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,578

SEC source: 0001062993-24-006350 · form4.xml · derivative · entry 2

NEUPERT PETER M · CIK 0001237566 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2024-03-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option was fully vested as of January 1, 2015.

SEC source: 0001062993-24-006350 · form4.xml · nonDerivative · entry 1

NEUPERT PETER M · CIK 0001237566 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,296

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-24-005766 · form4.xml · nonDerivative · entry 3

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 166,287

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-24-005766 · form4.xml · nonDerivative · entry 2

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 172,896

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-24-005758 · form4.xml · nonDerivative · entry 3

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,576,701

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-24-005758 · form4.xml · nonDerivative · entry 2

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,619,495

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-24-005768 · form4.xml · nonDerivative · entry 2

PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,318

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-24-005763 · form4.xml · nonDerivative · entry 3

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 253,745

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-24-005763 · form4.xml · nonDerivative · entry 2

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 255,558

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-24-005761 · form4.xml · nonDerivative · entry 3

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 472,754

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by Issuer's election under the equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-24-005761 · form4.xml · nonDerivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 486,244

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by Issuer's election under the equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-24-005762 · form4.xml · nonDerivative · entry 3

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 327,415

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-24-005762 · form4.xml · nonDerivative · entry 2

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 346,059

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-24-005759 · form4.xml · nonDerivative · entry 2

PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 531,553

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-24-005757 · form4.xml · nonDerivative · entry 3

BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 248,290

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-24-005757 · form4.xml · nonDerivative · entry 2

BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 255,265

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-24-005774 · form4.xml · derivative · entry 2

OWEN KATEY EINTERZ · CIK 0001852578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,044

Underlying: Common Stock · 48,044 shares

Expires 2034-03-04

F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2024, subject to continued service as a director through such vesting dates.

SEC source: 0001062993-24-005774 · form4.xml · nonDerivative · entry 1

OWEN KATEY EINTERZ · CIK 0001852578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,235

SEC source: 0001062993-24-005766 · form4.xml · derivative · entry 4

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,010

Underlying: Common Stock · 60,010 shares

Expires 2034-03-04

F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001062993-24-005766 · form4.xml · nonDerivative · entry 1

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 179,668

SEC source: 0001062993-24-005758 · form4.xml · nonDerivative · entry 1

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,625,374

SEC source: 0001062993-24-005768 · form4.xml · nonDerivative · entry 1

PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,045

SEC source: 0001062993-24-005763 · form4.xml · derivative · entry 5

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,024

Underlying: Common Stock · 150,024 shares

Expires 2034-03-04

F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001062993-24-005763 · form4.xml · nonDerivative · entry 1

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 268,445

SEC source: 0001062993-24-005761 · form4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 511,824

SEC source: 0001062993-24-005760 · form4.xml · nonDerivative · entry 1

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,021,180

SEC source: 0001062993-24-005775 · form4.xml · derivative · entry 2

Pellini Michael J · CIK 0001402017 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,044

Underlying: Common Stock · 48,044 shares

Expires 2034-03-04

F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2024, subject to continued service as a director through such vesting dates.

SEC source: 0001062993-24-005775 · form4.xml · nonDerivative · entry 1

Pellini Michael J · CIK 0001402017 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,296

SEC source: 0001062993-24-005773 · form4.xml · derivative · entry 2

NEUPERT PETER M · CIK 0001237566 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,044

Underlying: Common Stock · 48,044 shares

Expires 2034-03-04

F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2024, subject to continued service as a director through such vesting dates.